Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (114)

2024

  1. Novel biomarkers and psoriasis associated cardiovascular risk

    Archives of Dermatological Research, Vol. 316, Núm. 5

  2. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 4, pp. 1080-1093

2022

  1. Estándares SEA 2022 para el control global del riesgo cardiovascular

    Clínica e investigación en arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

2021

  1. Microvascular thrombosis and clinical implications

    Medicina Clinica, Vol. 156, Núm. 12, pp. 609-614

  2. Prediction and treatment of bleeding in patients under anticoagulant treatment

    Medicina Clinica, Vol. 156, Núm. 1, pp. 20-25

  3. Treatment of haemophilia: From replacement to gene therapy

    Medicina Clinica, Vol. 157, Núm. 12, pp. 583-587

2019

  1. Análisis de subpoblaciones monocitarias en relación con los factores de riesgo cardiovascular

    Clínica e investigación en arteriosclerosis, Vol. 31, Núm. 4, pp. 152-159

  2. Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 805-809

2018

  1. Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study

    PLoS ONE, Vol. 13, Núm. 8

2017

  1. Los pacientes con placas coronarias vulnerables presentan mayores niveles séricos de metaloproteinasa-1

    Anales del sistema sanitario de Navarra, Vol. 40, Núm. 1, pp. 35-42

  2. Reduced high-density lipoprotein cholesterol: A valuable, independent prognostic marker in peripheral arterial disease

    Journal of Vascular Surgery, Vol. 66, Núm. 5, pp. 1527-1533.e1

2016

  1. Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study

    European Journal of Haematology, Vol. 97, Núm. 2, pp. 128-136

2015

  1. Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study

    Thrombosis Research, Vol. 136, Núm. 6, pp. 1145-1148

  2. Increased levels of metalloproteinase 10 and hemostatic markers in patients with noncomplicated primary varicose veins

    Clinical and Applied Thrombosis/Hemostasis, Vol. 21, Núm. 7, pp. 684-687

  3. Matrix Metalloproteinase 10 Contributes To Hepatocarcinogenesis in a Novel Crosstalk With the Stromal Derived Factor 1/C-X-C Chemokine Receptor 4 Axis

    Hepatology, Vol. 62, Núm. 1, pp. 166-178

  4. Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease

    Journal of Vascular Surgery, Vol. 61, Núm. 2, pp. 428-435

  5. Short-term heparin re-exposure during heart transplantation in patients with ventricular assist devices and acute heparin-induced thrombocytopenia

    Revista Espanola de Cardiologia

2014

  1. Arteriosclerosis in the 21st century

    Angiologia, Vol. 66, Núm. 3, pp. 109-111

  2. Haemostatic activation and inflammatory response after three methods of treatment of great saphenous vein incompetence

    Phlebology, Vol. 29, Núm. 3, pp. 154-163

  3. Venous and arterial thrombosis: Similarities and clinical implications

    Medicina Clinica, Vol. 143, Núm. 1, pp. 20-21